Table of Contents

Research Articles

• Research Articles

  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer

  Ran You, Francesco J. DeMayo, Jian Liu, Sung-Nam Cho, Bryan M. Burt, Chad J. Creighton, Roberto F. Casal, Donald R. Lazarus, Wen Lu, Hui-Ying Tung, Xiaoyi Yuan, Andrea Hill-McAlester, Myunghoo Kim, Sarah Perusich, Loraine Cornwell, Daniel Rosen, Li-zhen Song, Silke Paust, Gretchen Diehl, David Corry and Farrah Kheradmand

  Cancer Immunol Res June 1 2018 6 (6) 645-657; DOI:10.1158/2326-6066.CIR-17-0554

  
  

  The pro-inflammatory cytokine IL17A has antitumor effects in certain subtypes of non–small cell lung cancer. Mice whose tumors were infiltrated with IL17A-expressing T cells were associated with increased lung cancer latency and had fewer metastasis.
• Research Articles

  Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells

  Luciano Castiello, Paola Sestili, Giovanna Schiavoni, Rosanna Dattilo, Domenica M. Monque, Fiorella Ciaffoni, Manuela Iezzi, Alessia Lamolinara, Antonella Sistigu, Federica Moschella, Anna Maria Pacca, Daniele Macchia, Maria Ferrantini, Ann Zeuner, Mauro Biffoni, Enrico Proietti, Filippo Belardelli and Eleonora Aricò

  Cancer Immunol Res June 1 2018 6 (6) 658-670; DOI:10.1158/2326-6066.CIR-17-0675

  
  

  Type I interferon (IFN-I) inhibits tumor growth and activates antitumor responses. HER2-driven tumors in mice lacking IFN-I receptor were more aggressive, more vascularized, and were enriched in stem cells, suggesting that IFN-I exerts key control over tumor progression.
• Research Articles | AuthorChoice

  Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

  Zhiwei Hu, Rulong Shen, Amanda Campbell, Elizabeth McMichael, Lianbo Yu, Bhuvaneswari Ramaswamy, Cheryl A. London, Tian Xu and William E. Carson III

  Cancer Immunol Res June 1 2018 6 (6) 671-684; DOI:10.1158/2326-6066.CIR-17-0343

  
  

  Expression of tissue factor (TF) on the cancer cells and tumor neovasculature of triple-negative breast cancer provides a target for immunotherapy. An improved TF-targeting second-generation immunoconjugate (called L-ICON1) was tested for immunotherapy of this malignancy in preclinical mouse models.
• Research Articles | AuthorChoice

  IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors

  Hyungseok Seo, Byung-Seok Kim, Eun-Ah Bae, Byung Soh Min, Yoon Dae Han, Sang Joon Shin and Chang-Yuil Kang

  Cancer Immunol Res June 1 2018 6 (6) 685-695; DOI:10.1158/2326-6066.CIR-17-0708

  
  

  Combination rIL21 and anti–PD-1/anti–Tim-3 additively enhanced NK cell responses in mice bearing MHCclass I–deficient tumors. This combination facilitated NK effector functions in cancer patients, highlighting its therapeutic potential for patients with MHC class I–deficient tumors.
• Research Articles | AuthorChoice

  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice

  Chih-Hang Anthony Tang, Shiun Chang, Ayumi Hashimoto, Yi-Ju Chen, Chang Won Kang, Anthony R. Mato, Juan R. Del Valle, Dmitry I. Gabrilovich and Chih-Chi Andrew Hu

  Cancer Immunol Res June 1 2018 6 (6) 696-710; DOI:10.1158/2326-6066.CIR-17-0582

  
  

  In a mouse model of chronic lymphocytic leukemia, production of secretory IgM led to more MDSCs, fewer T cells, and shorter survival times for the mice. Thus, secretory IgM may aggravate the progression of this cancer.
• Research Articles | AuthorChoice

  TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

  Ilaria Grazia Zizzari, Chiara Napoletano, Andrea Botticelli, Salvatore Caponnetto, Fabio Calabrò, Alain Gelibter, Aurelia Rughetti, Ilary Ruscito, Hassan Rahimi, Ernesto Rossi, Giovanni Schinzari, Paolo Marchetti and Marianna Nuti

  Cancer Immunol Res June 1 2018 6 (6) 711-722; DOI:10.1158/2326-6066.CIR-17-0594

  
  

  Pazopanib, a kinase inhibitor that targets angiogenesis, primed dendritic cells from patients with metastatic renal cell carcinoma and healthy donors. The resultant immune response indicates that this could be exploited to improve outcomes for patients undergoing combination immunotherapy.
• Research Articles

  PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF

  Girija Goyal, Karrie Wong, Christopher J. Nirschl, Nicholas Souders, Donna Neuberg, Niroshana Anandasabapathy and Glenn Dranoff

  Cancer Immunol Res June 1 2018 6 (6) 723-732; DOI:10.1158/2326-6066.CIR-17-0612

  
  

  PPARγ deficiency in myeloid cells reduced the efficacy of GVAX cancer vaccines, altered DC gene expression and function, and decreased the ratio of vaccine-induced CD8⁺ T cells to Tregs. Correspondingly, PPARγ agonists improved the efficacy of cancer immunotherapy.
• Research Articles

  Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs

  Kotaro Miyao, Seitaro Terakura, Shingo Okuno, Jakrawadee Julamanee, Keisuke Watanabe, Hiroshi Hamana, Hiroyuki Kishi, Reona Sakemura, Daisuke Koyama, Tatsunori Goto, Tetsuya Nishida, Makoto Murata and Hitoshi Kiyoi

  Cancer Immunol Res June 1 2018 6 (6) 733-744; DOI:10.1158/2326-6066.CIR-17-0538

  
  

  It may be safer to improve adoptive T-cell therapy through increased signaling rather than increased antigen affinity of the TCRs. Modifying intracellular signaling enhanced the proliferation and persistence of CTLs while improving antitumor efficacy.
• Research Articles

  Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

  Hiroshi Ureshino, Takero Shindo, Hiroto Kojima, Yasushi Kusunoki, Yuki Miyazaki, Hidenori Tanaka, Hiroh Saji, Atsushi Kawaguchi and Shinya Kimura

  Cancer Immunol Res June 1 2018 6 (6) 745-754; DOI:10.1158/2326-6066.CIR-17-0462

  
  

  In CML patients treated with tyrosine kinase inhibitors, KIR alleles were associated with patient outcome. The combination of alleles at KIR3DL1 and HLA-B loci were found to predict the therapeutic effects of tyrosine kinase inhibitor therapy.